Aschner, J L
Gien, J
Ambalavanan, N
Kinsella, J P
Konduri, G G
Lakshminrusimha, S
Saugstad, O D
Steinhorn, R H
Article History
Received: 15 October 2015
Revised: 10 February 2016
Accepted: 16 February 2016
First Online: 26 May 2016
Competing interests
: JLA, JG, NA, JPK, GGK, SL, ODS and RHS received honoraria for their participation in a roundtable meeting supported by a grant from Mallinckrodt Pharmaceuticals, formerly Ikaria. JLA is named on an intellectual property rights patent for the use of intravenous citrulline for neonatal lung diseases. NA has received research support from Pfizer and has received research support as a mentor from Ikaria. GGK has received consulting fees from Boston Health Economics and Actelion Clinical Research. SL was a member of the speaker’s bureau for Ikaria from June 2010 to October 2014 and has received grant support from the American Academy of Pediatrics and Canadian Pediatric Society. RHS has received research grant support from Pfizer. NIH Grants: 1U01HL101456 (JLA); U01 HL122626 and R01 HD067126 (NA); 5R01HD072929-03 (SL); 5R01HL057268-11 (GGK); 5R01HL054705-13 (RHS).
Free to read: This content has been made available to all.